Halozyme Therapeutics (HALO) EBITDA Margin (QoQ) (2010 - 2026)
Halozyme Therapeutics (HALO) EBITDA Margin (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,082.00 |
| Mar 31, 2026 | 6,954.00 |
| Dec 31, 2025 | -8,208.00 |
| Sep 30, 2025 | -64.00 |
| Jun 30, 2025 | 871.00 |
| Mar 31, 2025 | -545.00 |
| Dec 31, 2024 | 263.00 |
| Sep 30, 2024 | 558.00 |
| Jun 30, 2024 | 190.00 |
| Mar 31, 2024 | 486.00 |
| Dec 31, 2023 | 306.00 |
| Sep 30, 2023 | -187.00 |
| Jun 30, 2023 | 955.00 |
| Mar 31, 2023 | -787.00 |
| Dec 31, 2022 | 120.00 |
| Sep 30, 2022 | 1,750.00 |
| Jun 30, 2022 | -4,217.00 |
| Mar 31, 2022 | 910.00 |
| Dec 31, 2021 | -983.00 |
| Sep 30, 2021 | -293.00 |